Testing effectiveness (Phase 2)Ended earlyNCT04849910
What this trial is testing
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Vor Biopharma 67